NCT01030055View on ClinicalTrials.gov

Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
NeoplasmsCancerTumors
Interventions
DRUG

TKI258 (dovitinib)

bioavailability (anhydrate capsules) food (monohydrae capsules)

Trial Locations (4)

27710

Duke University Medical Center Cancer Dept, Durham

84112

University of Utah / Huntsman Cancer Institute, Salt Lake City

90095

University of California at Los Angeles, Los Angeles

91010

City of Hope National Medical Center, Duarte

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY